GNH USA

Europe — EMA

Meriofert Set

GNH USA supplies Meriofert Set (FSH/LH), a gonadotropin for anovulatory infertility and IVF stimulation. Request a quote for global worldwide supply.

Follicle-Stimulating Hormone, Luteinising Hormone

Request sourcing

1
Pack/s

What is Follicle-Stimulating Hormone, Luteinising Hormone?

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It treats infertility due to anovulation and is used in assisted reproductive technology protocols.

GNH USA supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics and pharmacies worldwide.

What is Follicle-Stimulating Hormone, Luteinising Hormone used for?

Meriofert Set acts on the reproductive hormone pathway to support ovarian function.

Anovulatory infertility: stimulates follicular development to induce ovulation. Assisted reproductive technology cycles: provides controlled ovarian stimulation for IVF, ICSI and related procedures. Intrauterine insemination (IUI) protocols: enhances follicle growth to improve pregnancy chances.

What are the side effects of Follicle-Stimulating Hormone, Luteinising Hormone?

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Headache. - Nausea. - Transient ovarian cyst formation. - Mild ovarian hyperstimulation.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe). - Multiple pregnancy (twins or higher order). - Allergic reaction or anaphylaxis. - Thromboembolic events. - Ectopic pregnancy. - Severe abdominal pain with rapid weight gain.

What precautions apply to Follicle-Stimulating Hormone, Luteinising Hormone?

Precautions should be observed to minimise risks and ensure optimal response.

Pregnancy testing: confirm non‑pregnant status before initiating therapy. Ovarian monitoring: perform serial ultrasound to assess follicular response. Risk of OHSS: monitor for signs and adjust dosage as needed. Allergy assessment: screen for hypersensitivity to gonadotropins. Concomitant medication review: evaluate drugs that may affect ovarian response. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Follicle-Stimulating Hormone, Luteinising Hormone interact with?

Potential drug interactions must be reviewed before treatment.

Major Interactions (Avoid): - GnRH antagonists: may blunt ovarian response. - High‑dose estrogen therapy: can reduce efficacy of gonadotropins.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may alter ovarian sensitivity. - Corticosteroids: can affect hormone metabolism. - Anticoagulants: increased risk of bleeding at injection sites.

Frequently asked questions

What is Meriofert Set used for?+
Meriofert Set is prescribed to treat infertility caused by anovulation and to support ovarian stimulation in assisted reproductive technology cycles such as in‑vitro fertilisation (IVF) or intrauterine insemination (IUI). It provides the necessary follicle‑stimulating and luteinising hormones to promote follicular growth and ovulation under specialist supervision.
How does Follicle‑Stimulating Hormone and Luteinising Hormone work?+
The two hormones bind to specific FSH and LH receptors on ovarian cells. This binding activates intracellular pathways that drive follicular maturation, estrogen production, luteinisation and the final ovulatory surge, creating a hormonal environment that enables egg release and improves the chances of successful conception.
What determines the usual dose of Meriofert Set?+
The exact dose is individualized and set by the treating reproductive specialist based on the patient’s age, ovarian reserve, previous response to stimulation and the specific assisted‑reproduction protocol. Clinicians calculate the amount required to achieve optimal follicular development while minimizing the risk of ovarian hyperstimulation.
Is Meriofert Set safe to use during pregnancy or breastfeeding?+
Meriofert Set is intended for use before conception and is not indicated for administration during an established pregnancy. Its safety in breastfeeding has not been established, so the product should only be used under the guidance of a fertility specialist who can assess risks and benefits for each individual.
How do I order Meriofert Set from GNH USA?+
To place an order, submit an enquiry on the Meriofert Set product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.
How does Meriofert Set compare with other gonadotropin products?+
Meriofert Set contains both FSH and LH in a single injectable formulation, similar to other combined gonadotropin preparations. Compared with recombinant single‑component products, it offers the convenience of a dual‑hormone dose but may differ in molecular structure and purity. Clinical choice depends on physician preference, patient response, and cost considerations.
What are the storage and handling requirements for Meriofert Set?+
The product must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles. Follow local pharmacy guidelines for cold‑chain management during transport.
How is Meriofert Set administered?+
Meriofert Set is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. Administration is performed by a qualified healthcare professional using aseptic technique. The injection site is typically the abdomen or thigh for subcutaneous delivery, or the gluteal muscle for intramuscular administration, as directed by the prescribing clinician.
What are the most serious risks associated with Meriofert Set?+
The most serious adverse events include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal pain and fluid accumulation, and the possibility of multiple pregnancy. Allergic reactions, including anaphylaxis, and rare thromboembolic complications have also been reported, requiring prompt medical attention.
Who should not use Meriofert Set?+
Meriofert Set is contraindicated in women who are already pregnant, have known hypersensitivity to gonadotropins, or have uncontrolled thyroid disease, ovarian cysts, or severe ovarian failure. Patients with active malignancy, uncontrolled hypertension, or a history of severe OHSS should also avoid its use unless a specialist determines that benefits outweigh risks.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Follicle-Stimulating Hormone, Luteinising Hormone
Route
Intramuscular Use , Subcutaneous Use
Manufacturer
Ibsa Farmaceutici Italia
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU